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Abstract
Background. Chronic myeloid leukemia (CML) constitutes only 2–3% of all leukemias in pediatric patients. 
Philapelphia chromosome and BCR-ABL fusion are genetic hallmarks of CML, and their presence is crucial 
for targeted molecular therapy with tyrosine kinase inhibitors (TKIs), which replaced hematopoietic stem 
cell transplantation (HSCT) as a standard first-line therapy. The disease in pediatric population is rare, and 
despite molecular and clinical similarities to CML in adults, different approach is needed, due to the long 
lifetime expectancy and distinct developmental characteristics of affected children.
Objectives. The objective of this study is to evaluate treatment with imatinib in Polish pediatric patients with CML.
Material and methods. We analyzed the results of treatment with imatinib in 57 pediatric patients (June 
2006 – January 2016) from 14 Polish pediatric hematology and oncology centers.
Results. In the study group, 40 patients continued imatinib (median follow-up: 23.4 months), while in 17 
the treatment was terminated (median follow-up: 15.1 months) due to therapy failure. In the latter group, 
13 patients underwent HSCT, while 4 switched to second-generation TKIs. The 5-year overall survival rate (OS) 
in the study group was 96%, and the 5-year event-free survival (EFS) was 81%.
Conclusions. Our results confirm that the introduction of TKI therapy has revolutionized the treatment 
of CML in the pediatric population by replacing the  previous method of treatment with HSCT and allowing 
a high percentage of OS and EFS.
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Material and methods
We  conducted a  retrospective, nation-wide analysis 
of the imatinib therapy results in children and adolescents 
with CML in Poland. The study group consisted of 57 pa-
tients (M = 35, F = 22) from 14 Polish pediatric hematology 
and oncology centers treated in 2006–2016. The majority 
of patients (n = 54) were diagnosed in the chronic phase 
and only 3 patients in the accelerated phase. The diagnosis 
of CML was made according to the 4th edition of WHO 
classification of hematopoietic and lymphoid tissues, with 
mandatory molecular confirmation of BCR-ABL fusion. 
The first-line treatment with imatinib was performed ac-
cordingly to previous I-BFM recommendations. Patients 
and/or their legal guardians signed the appropriate consents. 
The effectiveness of TKI therapy was evaluated on the ba-
sis of “milestones” of the therapy: complete hematologic 
remission (CHR); complete cytogenetic response (CCyR); 
and major molecular response (MMR). CHR was defined 
as leukocyte count <10 × 103/µL, <5% basophils and <450 × 
103/µL platelets in peripheral blood, absence of myelocytes, 
promyelocytes and blasts in the peripheral blood, and non-
palpable spleen during physical examination. Starting from 
the moment of CML diagnosis blood counts with blood 
smear should be performed every 15 days until achieving 
CHR, and then at least once every 3 months. Complete 
cytogenetic response (CCyR) was defined as the absence 
of Ph (+) cells in the bone marrow in classical cytogenet-
ics or the FISH method, and evaluated within 12 months 
of the treatment.
Partial cytogenetic response (PCyR) was the presence 
of 1–35% Ph (+) cells in the bone marrow. Minor and min-
imal cytogenetic response was the presence of 36–65% 
or 66–95% Ph (+) cells in the bone marrow, respectively. 
Cytogenetic evaluation was performed after 3 and 6 months 
after the implementation of imatinib, then every 6 months 
until CCyR achievement, and every 12 months thereafter 
or in the case of treatment failure. 
Molecular response was evaluated after 18 months 
of the treatment. Major molecular response (MMR) was 
defined as the BCR-ABL transcript level below 0.1% Mo-
lecular tests were performed every 3 months until MMR 
confirmation, and then not less than every 6 months. 
If there was an unsatisfactory response, testing for BCR-
ABL kinase domain mutations was performed. 
Statistical analysis
The statistical analysis was performed using STATIS-
TICA v. 10.0. As events in the analysis of event-free survival 
(EFS) we considered the following: death of the patient; 
switch to second-generation tyrosine kinase inhibitors 
(2G TKIs) due to therapy failure or imatinib intolerance; 
proceeding with HSCT due to  intolerance of  imatinib 
and/or loss of cytogenetic or molecular response during 
imatinib therapy.
Introduction
Chronic myeloid leukemia (CML) is a myeloprolifera-
tive neoplasm typically diagnosed in the adult popula-
tion and is relatively rare in children with the incidence 
of 0.6–1.2 million per year.1 CML is a clonal disorder of he-
matopoietic progenitor cells resulting from the balanced 
translocation (9;22) called the Philadelphia chromosome 
(Ph) at  the molecular level, resulting in  the  formation 
of a fusion gene BCR-ABL. The BCR-ABL protein encoded 
by the fusion gene exhibits tyrosine kinase activity and 
promotes uncontrolled proliferation of pluripotent stem 
cells in bone marrow (BM). CML has a 3-phase course: 
chronic phase (CML-CP); accelerated phase (CML-AP); 
and blast crisis phase (CML-BC). CML is most commonly 
diagnosed in the CML-CP and only in about 10% of cases 
in advanced phases: CML-AP or CML-BC.2
Before the implementation of imatinib, hydroxyurea +/- 
interferon alpha remained the first-line treatment of CML, 
followed by HSCT after achieving hematologic remission.3 
The  identification of  tyrosine kinase inhibitors (TKI) 
with BCR-ABL blocking ability revolutionized the CML 
therapy due to pharmacological control of leukemic clone. 
TKI-based therapy has proved to be very effective and 
quickly led to the withdrawal of HSCT as the first-line 
treatment. A first-generation TKI – imatinib was approved 
for the treatment of adult patients in 2001. Then, in 2003, 
it was approved, for the therapy in children. It should be 
emphasized that treatment with TKI is not a way to cure 
CML, as in most patients leukemia cells are still present. 
However, a unique feature of these drugs is a significant re-
duction of the risk of CML progression.2 In the era of TKIs, 
the CML-CP can last beyond 20 years.
The recommended starting dose of imatinib for chil-
dren is 260–300 mg/m2 (max daily dose: 400 mg) in CP, 
400 mg/m2 (max daily dose: 600 mg) in AP, and 500 mg/m2 
(max daily dose: 800 mg) in the blastic phase.3 In recent 
years, due to the development of the targeted therapy and 
the implementation of TKIs in pediatric patients, there 
has been significant progress in the treatment of CML, 
but the  data is  relatively limited due to  low incidence 
of CML. One should remember that long-term side effects 
of TKI therapy may occur, because the drug has only been 
in use for approx. 15 years. Despite the excellent results 
of imatinib therapy, one should not forget about HSCT. 
It is the only method for obtaining definite cure of CML. 
HSCT is the first-line treatment in patients with CML who 
have become resistant to the first- and second-generation 
TKIs, or when serious side effects of the therapy occur 
and there is a matched donor available. In some cases, 
the preference of HSCT by the patient or his/her parents 
is also very important. It is worth noting that HSCT should 
be considered more frequently in patients diagnosed with 
CML before puberty due to  growth impairment after 
TKI therapy. The transplant is  in fact the only method 
that can lead to the cure of this disease.
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Results
Study group
The  median age at  CML diagnosis was 13.6 years 
(the youngest child was 1.2 year, the oldest 17.9 years). 
The most commonly reported symptoms at the diagnosis 
were: asthenia (n = 22); weight loss (n = 18); abdominal pain 
(n = 17); fever (n = 16); limb pain (n = 10); and hemorrhage 
(n = 7). Other reported symptoms included ecchymoses 
(n = 4); headache (n = 4); diplopia (n = 2); pallor (n = 2); 
cough (n = 2); priapism (n = 2); breast pain (n = 1); night 
sweats (n = 1); arthritis (n = 1); dyspnoea (n = 1); polydip-
sia (n = 1); hair loss (n = 1); and intramuscular hematoma 
(n = 1). The most frequent signs were splenomegaly (n = 43; 
median size of the spleen was 5.5 cm below the costal mar-
gin), and hepatomegaly (n = 34; median size of the liver 
was 3 cm below the costal margin). In 8 cases, the diag-
nosis was set on the basis of routine blood tests without 
other accompanying symptoms. Laboratory tests revealed 
significant hyperleukocytosis in the majority of patients 
(median 226.28 103/µL, range 7.17–810 103/µL) and throm-
bocytosis (median 471 103/µL, range 27.9–3444.7 103/µL). 
During the follow-up period, 2 patients died, both after 
transplantation. One of them died on day +307 after HSCT 
from central nervous system aspergillosis and multiorgan 
failure, while the other died on day +76 after HSCT from 
grade IV acute Graft vs Host Disease (aGvHD) and pulmo-
nary hemorrhage. The 5-year OS in the study group was 
96% (Fig. 1) and the 5-year EFS was 79% (Fig. 2).
Treatment with imatinib
All pediatric patients were qualified for first-line treat-
ment with imatinib, according to CML-PAED II and I-
BFM-CML protocol. Hydroxyurea was administered 
as pre-imatinib cytoreductive phase in 21 patients (me-
dian duration: 16 days). In  1 case, anagrelide was ad-
ministered alternatively for the  treatment of CML-as-
sociated thrombocytosis. The median time of imatinib 
implementation from the  moment of  diagnosis was 7 
days (range 0–202  days). The  median initial dose was 
300 mg/m2 (range 220–468 mg/m2). The maximum dose 
was implemented in a single patient in CP, who had be-
come resistant to the standard doses and experienced lack 
of CCyR and MMR in 12 and 18 months after the initia-
tion of therapy, respectively. The dose of imatinib during 
therapy was modified in 23 cases. In 13 patients, the dose 
Fig. 1. 5-year overall survival (OS) in the study group (n = 57; alive = 55, died = 2)
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had to  be increased from 300  mg/m2 to  400  mg/m2 
due to  resistance to  imatinib therapy. In  10 patients, 
the imatinib dose was reduced due to toxicity (n = 8) or sat-
isfactory response to a higher dose (n = 2) (median dose 
after reduction: 170 mg/m2). Toxicity included myelotox-
icity (WHO grade 4, n = 1); thrombocytopenia (n = 1); 
leukopenia (n = 5); and headache (n = 1). In 4 patients, 
2G TKIs were implemented after imatinib: dasatinib in 3 
cases, and nilotinib in 1 case. In 19 patients, due to unsat-
isfactory response to imatinib, testing for BCR-ABL kinase 
domain mutations was performed. In 3 cases, the T315I 
mutation was confirmed, and all these patients underwent 
HSCT afterwards. In 1 case, ponatinib achieved molecular 
remission. 
Complete hematologic remission
Within 3 months complete chematologic remission 
(CHR) was achieved in 57 patients. In 2 patients, we ob-
served hematologic relapse. One patient underwent HSCT 
afterwards, and the other was switched to 2G TKI-nilo-
tinib and achieved another CHR.
Complete cytogenetic response
Within 12 months, complete cytogenetic response 
(CCyR) was evaluated in 45 out of 57 patients. In 4 cas-
es, the follow-up period did not exceed 1 year, 4 patients 
underwent HSCT in less than 12 months since the start 
of the treatment, 2 patients were transferred to an adult 
ward before the evaluation, while in 2 patients cytogenetic 
response was not assessed. Within 12 months from the on-
set of therapy, CCyR was achieved in 31/45 patients (i.e., 
69%). After 12 months, CCyR was observed in 9/45 cases 
(i.e., 20%). CCyR was not achieved in 5 cases (i.e., 11%). 
Out of the 5 patients who failed to achieve CCyR, 3 pa-
tients were switched to dasatinib, and 2 patients underwent 
HSCT afterwards. 
Major molecular response
After 18 months, major molecular response (MMR) was 
evaluated in 46 out of 57 patients. In 5 cases, the follow-up 
period did not reach 1.5 year. Four patients underwent HSCT 
in less than 18 months since the start of the treatment, 
Fig. 2. 5-year event free survival (EFS) in the study group (n = 57)
event free = 45; events = 12 (death of the patient; switch to 2G TKIs due to therapy failure or imatinib intolerance; HSCT due to intolerance of imatinib  
and/or loss of cytogenetic or molecular response during imatinib therapy).
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and 2 patients were transferred to an adult ward. MMR was 
achieved in 28/46 patients (i.e., 61%) after 18 months since 
the beginning of the treatment. MMR later than 18 months 
from therapy start was seen in 8/46 patients (i.e., 17%) with 
median time of 24 months. MMR was not achieved in 10/46 
cases (i.e., 22%). Five of these patients underwent HSCT 
afterwards, and 2 were switched to 2G TKI-dasatinib. 
In 3 cases, the dose of imatinib was increased, with con-
tinuous decrease in the BCR-ABL level. Characteristics 
of the study group and the results of treatment are sum-
marized in Table 1. 
Hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation (HSCT) was 
performed in 13 children (M = 9, F = 4). In 4 patients, 
the  transplant was performed in  the  1st CML-CP due 
to the local preferences of the center. In 3 patients, the rea-
son for HSCT was the advanced phase of CML (CML-BC, 
n = 1; CML-AP, n = 2), and these children were transplant-
ed in the 2nd CP (CML-CPII), after TKI treatment. Hema-
tologic toxicity of imatinib was the reason for a transplant 
in 1 case. In 5 other cases, the loss of molecular and/or cy-
togenetic response were observed. The donors were either 
matched unrelated (MUD: n = 9) or sibling (MSD: n = 4). 
Median time from the diagnosis of CML to HSCT was 
14.8 months (range 5.7–49 months). In 9 children, HSCT 
was performed in the 1st CP, and in 3 cases in the 2nd CP. 
In 1 case, a reduced-intensity conditioning regimen ac-
cording to CML-SCT I-BFM study was introduced. So far, 
tests have confirmed 100% allogenic chimerism and non-
detectable BCR-ABL (MR 4.5) in the patients’ peripheral 
blood, but the follow-up period is too short (2 months) 
to confirm the complete success of transplantation. 
Follow-up
Out of 57 patients enrolled in  the  treatment, 40 pa-
tients continue therapy with imatinib, while 17 completed 
the treatment. Thirty-five patients continue the therapy 
in pediatric centers (median follow-up: 33 months), and 
3 patients in adult centers, with which we are in constant 
contact (median follow-up: 93 months), while 2 patients 
were lost to follow-up treatment after being transferred 
to adult centers (status at the last contact: continuation 
of  the  TKI therapy). Among patients who completed 
the treatment, 13 underwent HSCT (2 patients died due 
to complications of the post-transplant period), and 4 pa-
tients were switched to second-generation TKIs (dasatinib, 
n = 3; nilotinib, n = 1).
Discussion
Clinical data concerning the treatment of CML in pe-
diatric population are limited because of its low incidence 
in children. It should be noted that for the purpose of our 
analysis we have gathered a relatively large group of pa-
tients (n = 57) compared with the available literature. 
The entire observation period amounted for 33 months 
in patients who continue the treatment in pediatric centers, 
and 93 months in patients who continue the treatment 
in adult centers.
Hematopoietic stem cell transplantation
Before the era of imatinib, HSCT was a standard first-
line therapy. Among pediatric patients who underwent 
transplantation from MSD in  the  1st chronic phase 
(CML-CP) in the years 1982–2004, EFS during the ob-
servation period of 3–5 years after HSCT ranged from 
61 to 63%. OS ranged from 66 to 87%.4,5  In transplant 
patients, MUD results were inferior, with EFS ranging 
from 27 to 55%, and OS from 45 to 65%.4–7 The main 
cause of death in both groups was acute and chronic 
GvHD, more common in children after MUD-HSCT. 
In patients transplanted in the advanced phase (CML-AP 
or CML-BC) or the 2nd chronic phase (CML-CPII), the re-
sults were worse with EFS from 34 to 35%, and OS from 
39 to 46%.6 In our study group, only 13 patients under-
went HSCT, which was mainly due to the good response 
to TKI therapy in most cases. OS among these children 
was 86%. We should remember that despite giving up 
the use of HSCT as a first-line therapy, it is still the only 
method by which we can completely eliminate leukemia 
cells and cure the disease.
Table  1. Characteristics of the study group. Results of treatment with 
imatinib in 57 pediatric patients (June 2006 – January 2016)  
from 14 Polish pediatric hematology and oncology centres
Study group Number of patients
Patients total
male
female 
57
35
22
Phase at the diagnosis
chronic phase
accelerated phase
54
3
Hematologic remission
complete hematologic remission (CHR)
hematologic relapse
55
2
Cytogenetic response evaluable
CCyR within 12 months 
CCyR after 12 months
failed to achieve CCyR
switch to dasatinib
HSCT
45/57
31 (69%)
9 (20%)
5 (11%)
2
3
Molecular response evaluable
MMR within 18 months
MMR after 18 months
failed to achieve
HSCT
switch to dasatinib
increase of the imatinib dose
46/57
28 (61%)
8 (17%)
10 (22%)
5
2
3
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to moderate and occur mainly in patients in whom TKI 
therapy was introduced in advanced phases of CML. Non-
hematological, relatively common side effects include 
nausea; vomiting; diarrhea; skin rash; swelling; limb pain; 
muscle spasms; bone and joint pain; headaches; weight 
gain; and an increase in liver enzymes.4,9,10,14 In one of our 
patients, we documented severe headaches, which resolved 
after a temporary decrease in the dose of imatinib. Millot 
et al. described neutropenia grade 3 or 4 in 27% of the chil-
dren receiving imatinib; thrombocytopenia grade 3 or 4 
in 5%; and anemia grade 3 or 4 in 2.5% of the patients.15 
However, these cytopenias were treatable by temporary 
discontinuation of  the  therapy or  the  administration 
of  granulocyte-colony stimulating factor (G-CSF) in some 
children with neutropenia. In 5 of our patients, we ob-
served leukopenia, and in 1 thrombocytopenia, which 
also resolved after a temporary dose reduction of  ima-
tinib. Only in 1 case, myelosuppression as a side effect after 
imatinib implementation was a reason for HSCT. Despite 
the potential cardiotoxicity, hepatotoxicity, immune dis-
orders and thyroid gland dysfunction observed in adults 
treated with imatinib, they have not been documented 
so far in children.16 In the group of pediatric patients with 
CML, the aspect of TKI therapy impact on bone metabo-
lism is very important. Imatinib impairs the differentiation 
and reduces the activity of osteoblasts and osteoclasts. 
This can result in growth retardation in children, particu-
larly those who are starting the treatment in prepuber-
tal age.13,17,18 In our study group, we observed no impact 
of imatinib on calcium and phosphate metabolism. We also 
noticed no abnormalities in serum phosphate, calcium, 
parathyroid hormone (PTH) and vitamin D levels or tu-
bular function disorders (phosphate absorption). However, 
we should keep in mind that particular attention should 
be paid in the group of the youngest patients chronically 
receiving TKI. They require regular and detailed clinical 
evaluation, and performing the panel of basic laboratory 
tests during each visit. Our results confirmed that the rec-
ommended daily dose of imatinib is well tolerated in pe-
diatric patients, and severe side effects are relatively rare.
Second-generation TKIs
2G TKIs – dasatinib and nilotinib – were registered 
for the treatment of adult patients with CML in 2006, 
and dasatinib only for the therapy of children in 2007. 
Nilotinib is not currently recommended for the treatment 
of pediatric patients. 2G TKIs are recommended when 
intolerance or resistance to imatinib occur.19,20 They are 
more effective in the treatment of CML due to the linking 
of both active and inactive conformations of the BCR-ABL 
protein. In addition, they show greater activity in the case 
of mutations of BCR-ABL gene, associated with resistance 
to TKI therapy.21 Unfortunately, there are an even more 
limited number of studies on the use of 2G TKIs in chil-
dren. The first reports are from 2011 as the results of the 1st 
Treatment with imatinib
One of the first trials with TKI in children was published 
in 2004 by the Children’s Oncology Group and it presented 
promising results.8 For the 2nd phase trial of this study, 31 pe-
diatric patients who experienced failure of interferon ther-
apy were qualified. In this group, all the children achieved 
CHR, and in 83% of them CCyR was observed. Another 
study covered 8 European countries and 30 patients were 
enrolled in it.9 CHR was achieved in 80% cases, and CCyR 
in 60% of the patients enrolled in the trial in the CP and 29% 
of the children enrolled in the AP. In half of the children, 
MMR was reported. Similar results were published in France, 
in the 4th phase study conducted on a group of 40 patients.10 
The average duration of the follow-up period in this study 
was 16 months. CHR within 3 months was achieved in 86% 
of the patients, and within 6 months in 98% of the patients. 
CCyR was observed in 62% of the children within 1 year 
after the inclusion of imatinib therapy, in 34% of them MMR 
within 18 months after initiation of the treatment was con-
firmed. Similar results were achieved in a German clini-
cal trial CML-PAED II published in year 2009.11 Out of 42 
enrolled patients, 40 achieved CHR within 3 months. In 26 
out of 28 patients, CCyR was observed within 1 year after 
the start of the treatment, and in 17 out of 19, MMR after 
18 months from the onset of the treatment. It should be 
emphasized that all patients from our study group are simul-
taneously registered in an international database I-CML-
Ped Study, so far consisting of 351 children diagnosed with 
CML. This study, aimed at optimizing the treatment of CML 
in children, is still ongoing. Preliminary results presented 
at the 56th American Society of Hematology (ASH) Annual 
Meeting are promising and comparable with the results 
of treatment achieved in the Polish population.12 Our study 
group consisted of 57 pediatric patients diagnosed in Po-
land with a median overall follow-up period of 31 months. 
CHR within 3 months after the implementation of the treat-
ment with imatinib was documented in all patients. CCyR 
after 12 months of therapy was observed in 69% of patients, 
while MMR in 61% of patients after 18 months of treatment. 
These results correspond with the quoted literature, in par-
ticular with the results of Suttorp et al.’s analysis from 2009, 
and the results of treatment in the context of clinical trial 
I-CML-Ped Study.11,12 Moreover, when comparing the pro-
portion of patients achieving CCyR and MMR, our results 
are above promising. However, despite the excellent results 
of imatinib therapy, one should not forget about HSCT. 
It is worth noting that HSCT should be considered more 
frequently in patients diagnosed with CML before puberty 
due to the fact that long-term TKI intake may in the future 
be the cause of short stature among these patients.13
Side effects of imatinib
TKI are usually well tolerated; however, some side ef-
fects may occur. In most cases, they are classified as mild 
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phase clinical trial conducted by the Children’s Oncology 
Group. Thirty-nine patients were enrolled for the treat-
ment with dasatinib, including 9 with CML who were re-
sistant to imatinib or who had had an adverse event after 
using it. In 8 patients, cytogenetic response was observed, 
in 3 CCyR, in 3 PCyR, in 1 minor, and in 1 minimal cy-
togenetic response. In 1 patient, the cytogenetic response 
was not possible to assess.22 The 1st phase study CA 180–
018 from 2013 was conducted on a group of 63 pediatric 
patients, 17 of whom were enrolled in the chronic phase 
of CML, and only 3 in the advanced phase. Among patients 
with CML-CP, CHR was achieved in 94%, CCyR in 82%, 
and MMR in 47%. Patients enrolled in the study in the ad-
vanced phase of CML achieved slightly worse results.23 
In our study group, dasatinib was administered in 3 pa-
tients, while nilotinib in 1 case. In all 4 cases, these drugs 
were implemented due to the failure of imatinib treatment. 
Patients continue the treatment with 2G TKIs with a sat-
isfactory outcome, and no side effects have been docu-
mented. Clinical trials on the use of 2G TKIs are being car-
ried out and are raising great hopes, especially in patients 
in whom imatinib has proven to be ineffective.
Discontinuation of the treatment
Observations in adult patients show that during the TKI 
therapy and after documenting the undetectable level 
of BCR- ABL over a period of 24 months or more, one 
can try to discontinue the treatment with imatinib.24–26 
In approx. 40% of these patients, one can confirm continu-
ous MMR despite cessation of the therapy. In our study 
group, the treatment was discontinued in 1 patient after 
continuous 26 months of the undetectable level of BCR-
ABL. The patient remained under constant control and, 
after 11 months of continuous MMR, molecular relapse 
was confirmed (level of BCR-ABL transcript 3%). Ima-
tinib was reintroduced and the patient achieved another 
MMR within 3 months. The results of controlled trials 
evaluating the efficacy of TKI withdrawal in the groups 
of pediatric patients are promising, but they have not been 
published yet.27 These results will be very important be-
cause of the potential side effects of  long-term therapy 
with imatinib.
Conclusions
Our results confirm that the introduction of TKI therapy 
has revolutionized the treatment of CML in the pediatric 
population by replacing the previous method of treatment 
with HSCT and allowing a high percentage of OS (96%) 
and EFS (81%). Although the use of TKIs and 2G TKIs 
is not a cure for CML, and only reduces the risk of disease 
progression significantly, the results of ongoing clinical 
trial evaluating the safety of the treatment withdrawal 
after confirming a continuous 24-month undetectable level 
of BCR-ABL are promising. Despite the initial enthusiasm 
due to the excellent results of TKI therapy, there are more 
reports confirming that the use of imatinib is not devoid 
of serious side effects. However, in our study group, we ob-
served in only 1 case myelotoxicity WHO grade 4, which 
was the reason for HSCT. We should keep in mind the fact 
that the goal of the therapy in pediatric patients should 
be rather to cure the disease than to suppress it, which 
can be achieved only by performing HSCT. In the context 
of very promising results of HSCT in pediatric patients 
with CML after reduced-intensity conditioning regimen, 
HSCT should be taken into consideration, especially 
in prepubertal children.
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